These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31240499)

  • 21. Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis Is Unaffected by Comorbidity Burden or Obesity: Data from a US Registry.
    Pappas DA; Etzel CJ; Crabtree M; Blachley T; Best J; Zlotnick S; Kremer JM
    J Rheumatol; 2020 Oct; 47(10):1464-1474. PubMed ID: 31941801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients - the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response - results from the multicenter observational ACT-POL study.
    Stajszczyk M; Jeka S; Juś A; Pawlak-Buś K
    Reumatologia; 2022; 60(2):92-100. PubMed ID: 35782029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
    Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
    Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
    Choy E; Caporali R; Xavier R; Fautrel B; Sanmarti R; Bao M; Devenport J; Pethö-Schramm A
    Rheumatology (Oxford); 2019 Jun; 58(6):1056-1064. PubMed ID: 30649524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
    Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study.
    Isaacs JD; Salih A; Sheeran T; Patel YI; Douglas K; McKay ND; Naisbett-Groet B; Choy E
    Rheumatol Adv Pract; 2019; 3(1):rkz010. PubMed ID: 31431998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies.
    Haraoui B; Casado G; Czirják L; Taylor A; Dong L; Button P; Luder Y; Caporali R
    Rheumatol Ther; 2019 Jun; 6(2):231-243. PubMed ID: 30859494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years.
    Farah Z; Ali S; Price-Kuehne F; Mackworth-Young CG
    Biologics; 2016; 10():59-66. PubMed ID: 27069354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
    Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials.
    Verhoeven MMA; Tekstra J; Jacobs JWG; Bijlsma JWJ; van Laar JM; Pethö-Schramm A; Borm MEA; Lafeber FPJ; Welsing PMJ
    Arthritis Care Res (Hoboken); 2022 Jun; 74(6):889-895. PubMed ID: 33253497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
    Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
    Arthritis Res Ther; 2018 Jul; 20(1):151. PubMed ID: 30029613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.
    Yazici A; Özdemir Işık Ö; Dalkılıç E; Koca SS; Pehlivan Y; Şenel S; Inanc N; Akar S; Yılmaz S; Soysal Gündüz Ö; Cefle A; Karakaş ÖF; Onen F
    Sci Rep; 2022 Dec; 12(1):21972. PubMed ID: 36539458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study.
    Nagy G; Géher P; Tamási L; Drescher E; Keszthelyi P; Pulai J; Czirják L; Szekanecz Z; Kiss G; Kovács L
    Rheumatol Adv Pract; 2022; 6(2):rkac038. PubMed ID: 35663154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.
    Haraoui B; Jamal S; Ahluwalia V; Fung D; Manchanda T; Khraishi M
    Rheumatol Ther; 2018 Dec; 5(2):551-565. PubMed ID: 30370468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study.
    Hilliquin P; Barnetche T; Baillet A; Flipo RM; Lespessailles E; Roux C; Fardellone P; Gilbert-Marceau A; Idier I; Constantin A; Shipley E; Baudens G; Saraux A
    Rheumatol Ther; 2021 Mar; 8(1):95-108. PubMed ID: 33216287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
    Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.